Sydney, Feb 29: Australian medical device innovator, EMVision, is set to advance its journey into the US healthcare market following a strategic US$10 million (approx. A$15.28 million) investment from Keysight Technologies.
This collaboration paves the way for EMVision’s cutting-edge portable brain scanner, the emu™ device, to undergo accelerated clinical trials and regulatory approvals, aiming for a significant presence in the global healthcare industry.
The funding bolsters EMVision’s capacity to increase production of the emu™ devices for use in extensive clinical trials across leading US stroke centers.
Keysight Technologies, with its US$26 billion market cap, marks its entry into the medical imaging innovation space through this investment, underscoring its commitment to advancing healthcare technology.
EMVision’s emu™ device represents a breakthrough in stroke care, enabling rapid bedside diagnostic imaging to facilitate quick, life-saving treatments.
Utilizing ultra-high frequency radio signals combined with AI, it allows healthcare professionals to perform immediate scans with minimal training, a game-changer for stroke and neurological care in diverse medical settings.
The partnership, which follows a 2022 OEM supply agreement granting EMVision exclusive rights to a critical neuroimaging component, highlights Keysight’s support for EMVision’s mission to revolutionize stroke outcomes with portable imaging technology.
Scott Kirkland, EMVision CEO, expressed enthusiasm for the investment as a validation of their mission to enhance global stroke care.
Huei Sin, President of Keysight Technologies’ Electronic Industrial Solutions Group, lauded the strengthened ties with EMVision, emphasizing the synergy between Keysight’s technology leadership and EMVision’s innovative brain scanning capabilities.
In addition to the emu™ device, EMVision is developing a compact, first responder scanner designed for quick deployment and diagnosis in emergency situations, further showcasing the potential of portable imaging in transforming patient care.
The investment deal grants Keysight a 8.73 per cent stake in EMVision through the issuance of 7,454,231 new shares, set to be finalized within days, reflecting a strategic move towards integrating advanced imaging solutions in healthcare without requiring shareholder approval.
Media & PR: editor@dailystraits.com. Copyright 2021–Present DailyStraits.com. All rights reserved.